Professor Isa Odidi is the Chairman, co-founder, CEO, and co-Chief Scientist of Intellipharmaceutics Incorporated, a publicly-traded pharmaceutical research, development, and manufacturing company that operates in Canada and the United States.
He is a pharmaceutical scientist, business entrepreneur, and trained innovator that is dedicated to bridging the world of innovation, science, design, and technology with a focus on how these tools can promote economic and social advancement in developing economies such as Nigeria.
Globally recognized as a prolific inventor, Professor Isa Odidi has expertise in manufacturing, commercialization, regulatory affairs, quality control, and drug development. He is a researcher who has published over a hundred scientific and medical papers, textbooks, and articles. His works have also been cited in several patents and publications.
A born innovator and leader, Professor Isa Odidi was the Vice President and Chief Scientific Officer of Research and Development and New Technologies at Biovail Corporation International before founding Intellipharmaceuticals. Professor Odidi’s technologies assisted the company to grow into a multi-billion dollar drug development company which is the first of its kind in Canada.
Professor Isa Odidi has held senior positions in academia, such as a Professor at Shenyang Pharmaceutical University, which is the first research institute in pharmaceutical sciences in China. He is an Adjunct Professor at the Institute for Molecular Medicine in California and a Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada.
A graduate of Ahmadu Bello University, Nigeria, Professor Odidi holds a B.Sc. Pharmacy from the reputable institution. He also holds M.Sc. Pharmaceutical Technology with distinction from Kings College, University of London, and a Ph.D. Pharmaceuticals from the School of Pharmacy, University of London. He bagged an MBA from Joseph L. Rotman School of Management, University of Toronto.
Professor Isa Odidi is a graduate of the Western Executive Program, Ivey School of Business at the University of Western Ontario, and a graduate of the Harvard University, Kennedy School Executive Education Program in Innovation for Economic Development.
He is the first and only Nigerian and African to set up a world-class pharmaceutical R&D and manufacturing company which have been listed and traded on four international stock exchanges and with headquarters in Canada.
Professor Odidi holds over 100 issued and pending pharmaceutical development patents in Europe, Canada, Japan, India, and the United States. He has developed multiple drug products that have gotten approval by the United States Food and Drug Administration and that are being provided to patients in Canada, the United States, and several parts of the world.